Q3: Buzzi delivers 7% growth, stronger balance sheet

07/11/25 -"In the first nine months of 2025, Buzzi reported consolidated net sales of €3,406.2 million, up 7.0% from €3,184.3 million a year earlier. The increase reflects ongoing portfolio adjustments rather ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

07/11/25

Download

You may also be interested by these reports :

07/11/25

Heidelberg Materials

Heidelberg Materials reported Q3 sales and Results from Current Operations (RCO) in line with expectations, driven by disciplined pricing and ...

07/11/25

Buzzi

In the first nine months of 2025, Buzzi reported consolidated net sales of €3,406.2 million, up 7.0% from €3,184.3 million a year earlier. The ...

07/11/25

CRH

CRH delivered another strong quarter, with total revenues rising 5% year-on-year to $11.1 billion, up from $10.5 billion in Q3 2024. Net income ...

06/11/25

CEMENT & AGGREGATES

Wars, AI, Stimulus — Cement Takes Off

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue